Semaglutide and Physical Activity for Obesity and Multimorbidity

Active, not recruitingOBSERVATIONAL
Enrollment

35

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

November 30, 2026

Conditions
Obesity MorbidMultimorbidityObesity
Interventions
COMBINATION_PRODUCT

Semaglutide 2.4 mg, total diet replacement, behavioural intervention

Patients receive a highly specialized interdisciplinary weight loss treatment comprising two phases. Firstly, they engage in a total diet replacement using Nupo for approximately three months to induce a maximal weight loss. After this and for the duration of the entire treatment period, patients receive Semaglutide 2.4 mg and behavioural dietary support to maintain the weight loss and improve health. The total treatment period is two years.

Trial Locations (1)

2650

Copenhagen University Hospital, Hvidovre, Hvidovre

All Listed Sponsors
lead

Hvidovre University Hospital

OTHER